Absci Surges on Positive Phase 1 Data for Hair Loss Drug and $100M Capital Raise
Absci shares soared 35% to $10.01 after early Phase 1 safety data for its hair-loss antibody ABS-201 showed no serious adverse events, and the company raised $100 million in a stock offering.
Markets
